Insider buying last 90 days
No open-market insider purchases were filed for BDX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BDX insider filing, plotted on the chart in Gekko.Open BDX in Gekko
NYSE: BDX
Becton, Dickinson (BDX) Stock Analysis & Forecast
$180.94−0.44 (−0.2%)
Close on Sep 18, 2026. Page updated Sep 19, 9:15 pm ET.
Gekko Brief
AI summaryBecton, Dickinson (BDX) closes at $180.94, down 0.2%, holding above both its 50-day average of $174.79 and its 200-day average of $161.12. The GekkoIndex reads 57.6, placing the stock in the Neutral zone, while the gap to Gekko Fair Value stands at -42%, with fair value estimated at $311.88. Shorter-term momentum has softened, with the one-month return at -3.6% even as the three-month and one-year returns remain strong at 25.7% and 56.1%.
Recent attention centers on portfolio moves and product rollout. Corient Private Wealth LP reduced its BDX stake by 9.4% in a recent quarter, according to a securities filing. Separately, BD expanded its pharmacy automation footprint with the deployment of the Vmax 160 system at Fairview, aimed at handling complex specialty and refrigerated medications. A dividend of $1.05 per share was also declared, alongside commentary framing the stock as undervalued relative to an estimated fair value near $196.
Looking ahead, the next earnings report is scheduled for 5 November 2026, before the open, 46 days out and beyond a typical 20-trading-day hold. The prior quarter saw an EPS beat of $2.90 against a $2.77 estimate, with an average absolute reaction of 6.1% across the last eight quarters. Seasonality over the next 20 trading days has averaged -2.9% across 5 years, rising in only 2 of them. Analyst coverage from 10 firms shows 5 buy and 5 hold ratings, with a consensus target of $195.67, an 8.1% upside from current levels.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $180.94200-day averageGekko Fair Value $311.88
Key stats
- Market cap
- $49.86B
- P/E ratio
- 31.6
- Forward P/E
- 13.8
- EPS, TTM
- $5.88
- Revenue, TTM
- $22.48B
- Profit margin
- 4.2%
- Dividend yield
- 2.29%
- Beta
- 0.28
- Volume
- 6.23M avg 1.87M
- 1-year return
- +56.1%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±3.5%
- 50-day average
- $174.79
- 200-day average
- $161.12
- Next earnings
- Nov 5 before open
- Shares outstanding
- 272.4M
Becton, Dickinson swing-trade checklist
Becton, Dickinson scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $180.94 is above the 50-day ($174.79) and 200-day ($161.12) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
57.6, Neutral
Reading 57.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
42.0% below
Price is 42% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 46 days
Next report Nov 5, 2026, 46 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.9% on average
From this point in the calendar, the next 20 trading days averaged −2.9% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Becton, Dickinson stock chart and price history
Becton, Dickinson closed at $180.94 on Sep 18, 2026, +56.1% over the past year, inside a 52-week range of $100.31 to $193.07.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.6%
- 3 months
- +25.7%
- 6 months
- +15.6%
- 1 year
- +56.1%
The full BDX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BDX in Gekko
Follow Becton, Dickinson through every session
Put BDX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BDX in GekkoFree for 7 days. No credit card required.
About Becton, Dickinson
Becton, Dickinson makes and sells medical technology worldwide, ranging from everyday medical supplies to advanced diagnostic and laboratory equipment. It is known for producing a wide array of devices used across hospitals, labs, and treatment settings, spanning drug delivery, diagnostics, and surgical care. Its customers include hospitals, clinics, research organizations, pharmaceutical companies, and members of the public who rely on its products indirectly through healthcare providers.
The company organizes its work into three areas. One focuses on medication delivery and IV access, covering catheters, syringes, needles, infusion systems, and diabetes care tools such as pen needles. Another centers on diagnostics and research, supplying blood and specimen collection products, automated testing systems for infections like tuberculosis, cytology tools, and cell analysis equipment used in oncology and immunology work. The third addresses surgical and interventional needs, including products for hernia repair, tissue grafts, and other biosurgery applications.
Shares of Becton, Dickinson trade on the NYSE under the ticker BDX.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- bd.com
Becton, Dickinson GekkoIndex: the smart money zone
Becton, Dickinson’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.6, in the Neutral zone, down 2.8 points over five sessions.
57.6Neutral
Down 2.8 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | +0.9% | −0.2% | ||
| Accumulation | 240 | +0.3% | +0.6% | ||
| Neutral (current zone) | 366 | +0.1% | +1.7% | ||
| Distribution | 32 | +1.0% | −1.9% | ||
| Selling | 1 | Too few readings yet | |||
Average BDX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BDX price, zone by zone.Track BDX in Gekko
Is Becton, Dickinson stock overvalued? Gekko Fair Value
Becton, Dickinson trades 42.0% below Gekko Fair Value of $311.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Becton, Dickinson shares are worth, recalculated every trading day.
$311.88
Gekko Fair Value, Sep 17, 2026
42.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BDX in Gekko
Becton, Dickinson insider and Congress trading
No open-market insider purchases were filed for Becton, Dickinson, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BDX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BDX, plotted on the chart in Gekko.Open BDX in Gekko
Buybacks
Becton, Dickinson has been buying back its own shares.
- Latest authorization
- $2.00B, Feb 9, 2026
- Bought back, quarter ended Jun 30, 2026
- $2.25B
- As a share of market cap
- 4.51%
- Trailing four quarters
- $3.00B
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold BDX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Becton, Dickinson earnings: next date and track record
Becton, Dickinson reports on Nov 5, 2026, before the open (46 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 46 days away
- EPS estimate
- $4.06
- Revenue estimate
- $5.11B
8 of 8reports beat the EPS estimate
±6.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 7, 2026 AI summary
- What they said
- BDX reported Q2 fiscal 2026 revenue of $4.7 billion, up 2.6% FX-neutral, with adjusted operating margin of 24.2% and adjusted EPS of $2.90, both exceeding expectations. Over 90% of the portfolio delivered mid-single-digit growth, with double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. The company confirmed Vitor Roque as permanent CFO and is executing its 'New BD' strategy focused on competing, innovating, and delivering through BD Excellence.
- Guidance
- Based on strong first-half performance and improved visibility, BDX raised its full-year adjusted EPS guidance. Management expressed confidence in continued execution despite headwinds in Alaris, vaccines, and China, which represent less than 10% of revenue.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 7, 2026 | $2.90 est $2.77 | $4.71B est $4.67B | +3.2% |
| Feb 9, 2026 | $2.91 est $2.80 | $4.49B est $5.15B | +4.0% |
| Nov 6, 2025 | $3.96 est $3.92 | $5.89B est $5.91B | +0.8% |
| Aug 7, 2025 | $3.68 est $3.40 | $5.51B est $5.49B | +12.2% |
| May 1, 2025 | $3.35 est $3.28 | $5.27B est $5.35B | −18.5% |
| Feb 5, 2025 | $3.43 est $2.99 | $5.17B est $5.10B | −6.3% |
| Nov 7, 2024 | $3.81 est $3.77 | $5.44B est $5.38B | −3.5% |
| Aug 1, 2024 | $3.50 est $3.31 | $4.99B est $5.08B | +0.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Becton, Dickinson stock forecast and analyst price targets
Analysts’ average 12-month price target for Becton, Dickinson is $195.67, +8.1% from the last close, from 10 firms rating the stock in the last 90 days.
$195.67consensus 12-month target, +8.1% from the last close
Now $180.94Avg $195.67
Low $175High $210
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 8 | Jefferies | $210 | +16.1% |
| Aug 30 | Bank of America Securities | $200 | +10.5% |
| Aug 17 | TD Cowen | $182 | +0.6% |
| Aug 14 | Citi | $208 | +15.0% |
| Aug 13 | Citi | $208 | +15.0% |
+1.7%average 20-day move after past Neutral readings
−2.9%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Becton, Dickinson seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Becton, Dickinson averaged −2.9% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.5% | 1 of 5 |
| Next 10 trading days | −2.2% | 2 of 5 |
| Next 15 trading days | −3.7% | 2 of 5 |
| Next 20 trading days | −2.9% | 2 of 5 |
| Next 30 trading days | −3.9% | 1 of 5 |
For scale, BDX’s typical 20-trading-day move in either direction is about 3.5%.
Becton, Dickinson market cap and key statistics
Becton, Dickinson’s market cap is $49.86B, with a P/E ratio of 31.6 and revenue of $22.48B over the last twelve months.
Valuation
- Market cap
- $49.86B
- P/E ratio
- 31.6
- Forward P/E
- 13.8
- EPS, TTM
- $5.88
- Gekko Fair Value
- $311.88
Trading
- Volume
- 6.23M
- Avg volume, 20 days
- 1.87M
- 52-week high
- $193.07
- 52-week low
- $100.31
- Shares outstanding
- 272.4M
Financials
- Revenue, TTM
- $22.48B
- Profit margin
- 4.2%
- Return on equity
- 6.6%
- Quarterly earnings growth, YoY
- −31.4%
Risk and income
- Beta
- 0.28
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±3.5%
- Dividend yield
- 2.29%
Becton, Dickinson stock news this week
3 headlines about Becton, Dickinson from the past week, newest first, each linking to the publisher.
- Corient Private Wealth LP Decreases Stake in Becton, Dickinson and Company $BDXDefense World, Sep 17
- BDX Deploys Vmax 160 to Advance Intelligent Pharmacy AutomationZacks Investment Research, Sep 15
- Becton Dickinson (BDX) Could Be 10% Undervalued As Dividend LandsSimply Wall Street, Sep 11
Becton, Dickinson peers
Becton, Dickinson’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
Becton, Dickinson stock FAQ
What is Becton, Dickinson’s market cap?
Becton, Dickinson’s market cap is $49.86B at the Sep 18, 2026 close of $180.94, with 272.4M shares outstanding. The shares trade on a P/E ratio of 31.6.
What is the Becton, Dickinson stock forecast?
The consensus analyst 12-month price target for Becton, Dickinson is $195.67, +8.1% from the last close. Of the 10 firms that rated the stock in the last 90 days, 5 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Becton, Dickinson stock overvalued or undervalued?
On Gekko’s estimate Becton, Dickinson is undervalued: the Sep 18, 2026 close of $180.94 is 42.0% below Gekko Fair Value of $311.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Becton, Dickinson report earnings next?
Becton, Dickinson is expected to report on Nov 5, 2026, before the market opens (46 days away). Analysts expect earnings of $4.06 per share on revenue of $5.11B. Becton, Dickinson beat the earnings estimate in 8 of its last 8 reports, moving 6.1% on average across the report.
What is Becton, Dickinson’s 52-week high and low?
Becton, Dickinson’s 52-week high is $193.07 and its 52-week low is $100.31; it closed at $180.94 on Sep 18, 2026, +56.1% over the past year.
Is Becton, Dickinson stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Becton, Dickinson the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.